Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Edward J. Wladis & Madhavi L. Kambam. (2022) Ophthalmic complications of immune checkpoint inhibitors. Orbit 41:1, pages 28-33.
Read now
Read now
Evangelia Papavasileiou, Sashank Prasad, Suzanne K. Freitag, Lucia Sobrin & Ann-Marie Lobo. (2016) Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature. Ocular Immunology and Inflammation 24:2, pages 140-146.
Read now
Read now
Tobias Hager & B Seitz. (2014) Ocular side effects of biological agents in oncology: what should the clinician be aware of?. OncoTargets and Therapy 7, pages 69-77.
Read now
Read now
Articles from other publishers (32)
Tian Xia, Peter Bracha, Nirali Bhatt, Tomas Aleman & Alexander Brucker. (2023) CHOROIDAL NEOVASCULAR MEMBRANES ASSOCIATED WITH PAPILLITIS IN A PATIENT ON CHECKPOINT INHIBITOR. RETINAL Cases & Brief Reports 17:5, pages 625-629.
Crossref
Crossref
Swathi Somisetty, Ahmad Santina, David Sarraf & William F. Mieler. (2023) The Impact of Systemic Medications on Retinal Function. Asia-Pacific Journal of Ophthalmology 12:2, pages 115-157.
Crossref
Crossref
A. Martens, P. P. Schauwvlieghe, A. Madoe, I. Casteels & S. Aspeslagh. (2023) Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. Journal of Ophthalmic Inflammation and Infection 13:1.
Crossref
Crossref
Florence Chaudot, Pascal Sève, Antoine Rousseau, Alexandre Thibault Jacques Maria, Pierre Fournie, Pierre Lozach, Jeremy Keraen, Marion Servant, Romain Muller, Baptiste Gramont, Sara Touhami, Habeeb Mahmoud, Pierre-Antoine Quintart, Stéphane Dalle, Olivier Lambotte, Laurent Kodjikian & Yvan Jamilloux. (2022) Ocular Inflammation Induced by Immune Checkpoint Inhibitors. Journal of Clinical Medicine 11:17, pages 4993.
Crossref
Crossref
Natalia V. Tkachenko, Svetlana G. Belekhova, Natalia V. Zhukova, Vera S. Prokopchuk & Natalya S. Chernova. (2022) A clinical case of the development of choroidal neovascularization in a patient with skin melanoma on the background of therapy with MEK and BRAF inhibitors. Ophthalmology Reports 15:1, pages 77-85.
Crossref
Crossref
Madalena Cipriano, Katharina Schlünder, Christopher Probst, Kirstin Linke, Martin Weiss, Mona Julia Fischer, Lena Mesch, Kevin Achberger, Stefan Liebau, Marina Mesquida, Valeria Nicolini, Anneliese Schneider, Anna Maria Giusti, Stefan Kustermann & Peter Loskill. (2022) Human immunocompetent choroid-on-chip: a novel tool for studying ocular effects of biological drugs. Communications Biology 5:1.
Crossref
Crossref
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Marie Helene Errera, Hitesh Agrawal, Marco Lupidi & Jay Chhablani. (2022) Retinal toxicities of systemic anticancer drugs. Survey of Ophthalmology 67:1, pages 97-148.
Crossref
Crossref
Anam Mazharuddin, Dan S. Gombos & Nagham Al-Zubidi. 2022. Global Perspectives in Ocular Oncology. Global Perspectives in Ocular Oncology
337
347
.
Subahari Raviskanthan, Melissa M. Chu, Peter W. Mortensen, Andrew G. Lee & Nagham Al-Zubidi. 2022. Managing Immunotherapy Related Organ Toxicities. Managing Immunotherapy Related Organ Toxicities
231
253
.
Carmen Alba-Linero & Emilio Alba. (2021) Ocular side effects of checkpoint inhibitors. Survey of Ophthalmology 66:6, pages 951-959.
Crossref
Crossref
Kevin F. ElwoodJose S. Pulido, Shelley Day GhafooriC. Armitage HarperRobert W. Wong. (2021) CHOROIDAL NEOVASCULARIZATION AND CHORIORETINAL ATROPHY IN A PATIENT WITH MELANOMA-ASSOCIATED RETINOPATHY AFTER IPILIMUMAB/NIVOLUMAB COMBINATION THERAPY. RETINAL Cases & Brief Reports 15:5, pages 514-518.
Crossref
Crossref
Bliss Elizabeth O'Bryhim, Yevgeniy Sychev & Prabakar Kumar Rao. (2021) BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE. RETINAL Cases & Brief Reports 15:3, pages 230-233.
Crossref
Crossref
Blake H. Fortes, Prashant D. Tailor & Lauren A. Dalvin. (2021) Ocular Toxicity of Targeted Anticancer Agents. Drugs 81:7, pages 771-823.
Crossref
Crossref
Frederick “Fritz” T. Fraunfelder & Frederick “Rick” W. Fraunfelder. 2021. Drug-Induced Ocular Side Effects. Drug-Induced Ocular Side Effects
299
360
.
Xiaowei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang & Li Zhang. (2020) Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer 11:3, pages 810-818.
Crossref
Crossref
M. Majem, E. García-Martínez, M. Martinez, E. Muñoz-Couselo, D. Rodriguez-Abreu, R. Alvarez, A. Arance, A. Berrocal, L. de la Cruz-Merino & J. A. Lopez-Martin. (2020) SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clinical and Translational Oncology 22:2, pages 213-222.
Crossref
Crossref
Vinodh Kakkassery, Steffen Emmert, Dirk Rades, Nikolas von Bubnoff, Mahdy Ranjbar, Salvatore Grisanti, Argyrios Chronopoulos, Ludwig M. Heindl & Irenäus A. Adamietz. (2020) Der augenärztliche Notfall bei TumorpatientenOphthalmic emergencies in tumor patients. Der Onkologe 26:2, pages 151-156.
Crossref
Crossref
Manisha Reddy, Judy J. ChenAnanda KalevarRyan Terribilini & Anita Agarwal. (2020) IMMUNE RETINOPATHY ASSOCIATED WITH NIVOLUMAB ADMINISTRATION FOR METASTATIC NON–SMALL CELL LUNG CANCER. RETINAL Cases & Brief Reports 14:2, pages 120-126.
Crossref
Crossref
Giulia Corradetti, Sara Violanti, Adrian Au & David Sarraf. (2019) Wide field retinal imaging and the detection of drug associated retinal toxicity. International Journal of Retina and Vitreous 5:S1.
Crossref
Crossref
Vivian Paraskevi Douglas, Konstantinos A.A. Douglas & Dean M. Cestari. (2019) Immune checkpoint inhibitors. Current Opinion in Ophthalmology 30:6, pages 426-433.
Crossref
Crossref
Sara Touhami, Isabelle Audo, Céline Terrada, Alain Gaudric, Phuc LeHoang, Valérie Touitou & Bahram Bodaghi. (2019) Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. Progress in Retinal and Eye Research 72, pages 100761.
Crossref
Crossref
Esmée P. Hoefsmit, Elisa A. Rozeman, John B.A.G. Haanen & Christian U. Blank. (2019) Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open 4:4, pages e000472.
Crossref
Crossref
Lauren A. Dalvin, Carol L. Shields, Marlana OrloffTakami SatoJerry A. Shields. (2018) CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina 38:6, pages 1063-1078.
Crossref
Crossref
Mary Elizabeth Davis & Jasmine H. Francis. (2017) Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology. Seminars in Oncology Nursing 33:4, pages 415-424.
Crossref
Crossref
Bernardo Leon Rapoport, Ronwyn van Eeden, Vincent Sibaud, Joel B. Epstein, Jean Klastersky, Matti Aapro & Devan Moodley. (2017) Supportive care for patients undergoing immunotherapy. Supportive Care in Cancer 25:10, pages 3017-3030.
Crossref
Crossref
Jessica C. Hassel, Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas K. Eigentler, Marc-Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze, Jörg Trojan, Lisa Zimmer & Ralf Gutzmer. (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews 57, pages 36-49.
Crossref
Crossref
Bernardo L. Rapoport & Ronwyn van Eeden. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Laura Hahn & Kathryn L. Pepple. (2016) Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. Journal of Ophthalmic Inflammation and Infection 6:1.
Crossref
Crossref
Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer & Ralf Gutzmer. (2016) Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:7, pages 662-683.
Crossref
Crossref
Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer & Ralf Gutzmer. (2016) Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:7, pages 662-681.
Crossref
Crossref
Joëlle Antoun, Cherif Titah & Isabelle Cochereau. (2016) Ocular and orbital side-effects of checkpoint inhibitors: a review article. Current Opinion in Oncology 28:4, pages 288-294.
Crossref
Crossref
. (2013) Ipilimumab. Reactions Weekly 1469:1, pages 27-27.
Crossref
Crossref